VistaGen’s oral NMDA receptor glycine B antagonist in Phase 2 development for adjunctive treatment of major depressive disorder.
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2018 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc.(NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet need, today announced receiving Notices of Allowance from IP Australia and the Japan Patent Office (JPO) related to methods of treating depression with AV-101, VistaGen’s oral NMDA (N-methyl-D-aspartate) receptor glycine B antagonist in Phase 2 development for adjunctive treatment of major depressive disorder (MDD).
“These patents, when issued, will extend our commercial protection of AV-101 into Australia and Japan, two additional major pharmaceutical markets,” stated Shawn Singh, Chief Executive Officer of VistaGen. “As we continue to move forward with our clinical development of AV-101 for adjunctive treatment of MDD, having important AV-101 intellectual property outside of the U.S. and Europe is essential for potential strategic partnering opportunities in selected regional markets and to support our mission to bring new treatment alternatives for CNS conditions with unmet need to individuals around the world.”
About VistaGen
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing new generation medicines for multiple CNS diseases and disorders with high unmet need. For more information, please visit www.vistagen.com and connect with VistaGen on Twitter, LinkedIn and Facebook.
About AV-101
AV-101 is an investigational, orally bioavailable, small molecule NMDA (N-methyl-D-aspartate) receptor glycine B antagonist with the potential to be a treatment for multiple CNS indications with high unmet need. AV-101 is currently in Phase 2 clinical development in the United States for adjunctive treatment of MDD. The FDA has granted Fast Track designation for development of AV-101 as both a potential adjunctive treatment of MDD and as a non-opioid treatment for neuropathic pain.
